文献速递妇科

辅助化疗剂量调整是否影响晚期卵巢癌患者的结局?一项NRG肿瘤学/妇科肿瘤组研究

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
PubMed 文献 · Gynecol Oncol · 2018-08-19

本研究基于妇科肿瘤组III期试验方案182,纳入完成8个周期卡铂联合紫杉醇化疗的III期和IV期上皮性卵巢癌及原发性腹膜癌患者738例,其中229例(31%)需要剂量调整。调整剂量患者的疾病进展调整风险比为1.43(95%CI 1.19-1.72,P<0.001),死亡调整风险比为1.26(95%CI 1.04-1.54,P=0.021)。结论认为剂量调整患者疾病进展和死亡风险更高,需要化疗剂量调整可能识别出晚期上皮性卵巢癌和原发性腹膜癌中结局较差的高危患者。

要点

  • 738例完成8周期卡铂联合紫杉醇化疗的晚期上皮性卵巢癌和原发性腹膜癌患者中,229例(31%)需要剂量调整。
  • 剂量调整患者疾病进展调整HR为1.43(95%CI 1.19-1.72,P<0.001),死亡调整HR为1.26(95%CI 1.04-1.54,P=0.021)。
  • 剂量调整患者使用G-CSF的OR为3.63(95%CI 2.51-5.26,P<0.001),高于未调整患者。

核心结论

  • 剂量调整患者疾病进展和死亡风险更高,需要化疗剂量调整可能识别出晚期上皮性卵巢癌和原发性腹膜癌中结局较差的高危患者。

研究设计与样本

  • 基于妇科肿瘤组III期试验方案182,纳入完成8个周期卡铂联合紫杉醇化疗的III期和IV期上皮性卵巢癌及原发性腹膜癌患者738例,按剂量调整和G-CSF使用分组,主要终点为总生存期。

主要发现

  • 738例中229例(31%)需要剂量调整,509例未调整,两组人口学和预后因素均衡。
  • 剂量调整患者疾病进展调整HR为1.43(95%CI 1.19-1.72,P<0.001),死亡调整HR为1.26(95%CI 1.04-1.54,P=0.021)。
  • 剂量调整患者使用G-CSF的OR为3.63(95%CI 2.51-5.26,P<0.001),高于未调整患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin and paclitaxel. METHODS: Women with stages III and IV EOC and PPC treated on the Gynecologic Oncology Group phase III trial, protocol 182, who completed eight cycles of carboplatin with paclitaxel were evaluated in this study. The patients were grouped per dose modification and use of granulocyte colony stimulating factor (G-CSF). The primary end point was OS; Hazard ratios (HR) for PFS and OS were calculated for patients who completed eight cycles of chemotherapy. Patients without dose modification were the referent group. All statistical analyses were performed using the R programming language and environment. RESULTS: A total of 738 patients were included in this study; 229 (31%) required dose modification, 509 did not. The two groups were well-balanced for demographic and prognostic factors. The adjusted hazard ratios (HR) for disease progression and death among dose-modified patients were: 1.43 (95% CI, 1.19-1.72, P < 0.001) and 1.26 (95% CI, 1.04-1.54, P = 0.021), respectively. Use of G-CSF was more frequent in dose-modified patients with an odds ratio (OR) of 3.63 (95% CI: 2.51-5.26, P < 0.001) compared to dose-unmodified patients. CONCLUSION: Dose-modified patients were at a higher risk of disease progression and death. The need for chemotherapy dose modification may identify patients at greater risk for adverse outcomes in advanced stage EOC and PPC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Olawaiye AB, Java JJ, Krivak TC, et al. Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018. PMID: 30135020. doi:10.1016/j.ygyno.2018.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。